secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001104659-25-094724
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix updates AXPAXLI trials: SOL-1 topline Q1 2026, SOL-R H1 2027; initiates NPDR Phase 3
--------------------------------------------------------------------------------

- SOL-1 Phase 3 wet AMD trial topline results expected Q1 2026; retention >95%, rescue events >95% meet criteria, no new safety signals.
- SOL-R Phase 3 wet AMD trial enrollment completed, randomization ongoing; topline results expected H1 2027.
- Plans to initiate SOL-X long-term extension trial following SOL-1/SOL-R; subjects receive AXPAXLI every 24 weeks for 3 years.
- Initiates Phase 3 NPDR program with HELIOS-2 (432 subjects) and HELIOS-3 (930 subjects); FDA SPA agreement for HELIOS-2 design.
- Received notice of allowance from USPTO for patent covering treating ocular diseases with AXPAXLI; expiration expected 2044.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/0001104659-25-094724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/tm2527344d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-094724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer